Targets › TRPM8
4 programs from 4 companies in 7 trials: 3 Phase 3, 2 Phase 2, 2 Phase 4; Neurology, Respiratory, Immunology; next expected readout Dec 2026.
Non-selective ion channel permeable to monovalent and divalent cations, including Na(+), K(+), and Ca(2+), with higher permeability for Ca(2+). Activated by multiple factors, such as temperature, voltage, pressure, and changes in osmolality. (UniProt, Q7Z2W7)
Open in Phaseline: the race on TRPM8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Center For Sight | TRYPTYR (Acoltremon ophthalmic solution 0.003%) TRPM8 channel agonist | TRPM8 | Phase 4 | Sjogren Syndrome With Keratoconjunctivitis | Dec 2026 |
| Sport and Spine Rehab Clinical Research Foundation | Menthol Transient receptor potential cation channel subfamily M member 8 opener; Transient receptor potential cation channel subfamily A member 1 opener | TRPM8, TRPA1 | Phase 4 | Chronic Low Back Pain | – |
| TriGemX Bio | Elismetrep (K-304) Transient receptor potential cation channel subfamily M member 8 inhibitor | TRPM8 | Phase 3 | Migraine; Acute Migraine | Feb 2027 |
| Region Skane | Menthol Transient receptor potential cation channel subfamily M member 8 opener; Transient receptor potential cation channel subfamily A member 1 opener | TRPM8, TRPA1 | Phase 2 | Interstitial Lung Disease (ILD); Asthma | Feb 2027 |
Migraine (2) Acute Migraine (1) Interstitial Lung Disease (ILD) (1) Asthma (1) Sjogren Syndrome With Keratoconjunctivitis (1) Chronic Low Back Pain (1)
small molecule (4)
TriGemX Bio (1) Region Skane (1) Center For Sight (1) Sport and Spine Rehab Clinical Research Foundation (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.